Discover our new oral solid dose (OSD) development capabilities at our Bend, Oregon site.
Some drug developers diligently design scalability into their formulations from day one and are fully prepared for larger-scale production during Phase III. More often than not, however, problems inevitably surface in Phase III that can be difficult to predict, regardless of whether the project involves tablets, vials or another delivery format.
Download “Manufacturing Process Scale-up for Phase III: Clear Sailing or Storms Ahead?” to learn how building scalability into formulation throughout drug development, as well as transferring the project to a knowledgeable CDMO in Phase III, can help mitigate some of the challenges that arise in Phase III.